Transmucular Quadratus Lumborum Block: Potential Quadriceps Muscle Weakness

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 2, 2021

Primary Completion Date

November 28, 2021

Study Completion Date

November 28, 2021

Conditions
Neuromuscular Blockade
Interventions
DRUG

Ropivacaine

30 mL Ropivacaine 0,75% administered as a unilateral TQL block

OTHER

Quadriceps muscle strength

Quadriceps muscle strength is assessed using a hand-held dynamometer. Each participant is tested pre block administration and 60 minutes after

OTHER

Timed Up and Go

To test mobilisation the standardised Timed Up and Go test is used. Each participant is tested pre block administration and 60 minutes after

OTHER

Single-leg 6 meter timed hop test

To test muscle strength and power the single-leg 6 meter jump test is used. Each participant is tested pre block administration and 60 minutes after

OTHER

Temperature discrimination

Dermatomal evaluation of cold and warm discrimination of the thoracic and lumbar dermatomes Approximately 60 minutes after block administration

OTHER

Pinprick test

"Dermatomal evaluation of pinprick/sharp sensation of the thoracic and lumbar dermatomes.~Approximately 60 minutes after block administration"

DIAGNOSTIC_TEST

Blood samples

As a substudy the maximum serum concentration of ropivacaine is analyzed. Blood samples are taken at 0, 15, 30, 45 and 60 minutes after block administration

DIAGNOSTIC_TEST

Non-invasive blood pressure measurement

Non-invasive blood pressure is measured prior to block administration and 30 minutes after block administration

Trial Locations (1)

4000

Department of Anaesthesiology and Intensive Care Medicine, Zealand University Hospital, Roskilde, Roskilde

All Listed Sponsors
lead

Zealand University Hospital

OTHER

NCT05023343 - Transmucular Quadratus Lumborum Block: Potential Quadriceps Muscle Weakness | Biotech Hunter | Biotech Hunter